Gary McLean1, Julie Langan Martin2, Daniel J Martin2, Bruce Guthrie3, Stewart W Mercer4, Daniel J Smith2. 1. Institute of Health and Wellbeing, University of Glasgow, 1 Horselethill Road, Glasgow G12 9LX, UK. Electronic address: Gary.McLean@glasgow.ac.uk. 2. Institute of Health and Wellbeing, University of Glasgow, Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow G12 0XH, UK. 3. Quality, Safety and Informatics Research Group, University of Dundee, Mackenzie Building, Kirsty Semple Way, Dundee DD2 4BF, UK. 4. Institute of Health and Wellbeing, University of Glasgow, 1 Horselethill Road, Glasgow G12 9LX, UK.
Abstract
BACKGROUND: Schizophrenia is associated with increased cardiovascular mortality. Although cardiovascular disease (CVD) risk prediction algorithms are widely in the general population, their utility for patients with schizophrenia is unknown. METHODS: A primary care dataset was used to compare CVD risk scores (Joint British Societies (JBS) score), cardiovascular risk factors, rates of pre-existing CVD and age of first diagnosis of CVD for schizophrenia (n=1997) relative to population controls (n=215,165). RESULTS: Pre-existing rates of CVD and the recording of risk factors for those without CVD were higher in the schizophrenia cohort in the younger age groups, for both genders. Those with schizophrenia were more likely to have a first diagnosis of CVD at a younger age, with nearly half of men with schizophrenia plus CVD diagnosed under the age of 55 (schizophrenia men 46.1% vs. control men 34.8%, p<0.001; schizophrenia women 28.9% vs. control women 23.8%, p<0.001). However, despite high rates of CVD risk factors within the schizophrenia group, only a very small percentage (3.2% of men and 7.5% of women) of those with schizophrenia under age 55 were correctly identified as high risk for CVD according to the JBS risk algorithm. CONCLUSION: The JBS2 risk score identified only a small proportion of individuals with schizophrenia under the age of 55 as being at high risk of CVD, despite high rates of risk factors and high rates of first diagnosis of CVD within this age group. The validity of CVD risk prediction algorithms for schizophrenia needs further research.
BACKGROUND:Schizophrenia is associated with increased cardiovascular mortality. Although cardiovascular disease (CVD) risk prediction algorithms are widely in the general population, their utility for patients with schizophrenia is unknown. METHODS: A primary care dataset was used to compare CVD risk scores (Joint British Societies (JBS) score), cardiovascular risk factors, rates of pre-existing CVD and age of first diagnosis of CVD for schizophrenia (n=1997) relative to population controls (n=215,165). RESULTS: Pre-existing rates of CVD and the recording of risk factors for those without CVD were higher in the schizophrenia cohort in the younger age groups, for both genders. Those with schizophrenia were more likely to have a first diagnosis of CVD at a younger age, with nearly half of men with schizophrenia plus CVD diagnosed under the age of 55 (schizophreniamen 46.1% vs. control men 34.8%, p<0.001; schizophreniawomen 28.9% vs. control women 23.8%, p<0.001). However, despite high rates of CVD risk factors within the schizophrenia group, only a very small percentage (3.2% of men and 7.5% of women) of those with schizophrenia under age 55 were correctly identified as high risk for CVD according to the JBS risk algorithm. CONCLUSION: The JBS2 risk score identified only a small proportion of individuals with schizophrenia under the age of 55 as being at high risk of CVD, despite high rates of risk factors and high rates of first diagnosis of CVD within this age group. The validity of CVD risk prediction algorithms for schizophrenia needs further research.
Authors: Debra L Foley; Andrew Mackinnon; Vera A Morgan; Gerald F Watts; David J Castle; Anna Waterreus; Cherrie A Galletly Journal: Schizophr Bull Date: 2016-05-05 Impact factor: 9.306
Authors: Quintí Foguet-Boreu; Maria Isabel Fernandez San Martin; Gemma Flores Mateo; Edurne Zabaleta Del Olmo; Luís Ayerbe García-Morzon; Maria Perez-Piñar López; Luis Miguel Martin-López; Javier Montes Hidalgo; Concepción Violán Journal: BMC Psychiatry Date: 2016-05-12 Impact factor: 3.630
Authors: I H Heiberg; R Nesvåg; L Balteskard; J G Bramness; C M Hultman; Ø Naess; T Reichborn-Kjennerud; E Ystrom; B K Jacobsen; A Høye Journal: Acta Psychiatr Scand Date: 2020-02-29 Impact factor: 6.392
Authors: I H Heiberg; B K Jacobsen; L Balteskard; J G Bramness; Ø Naess; E Ystrom; T Reichborn-Kjennerud; C M Hultman; R Nesvåg; A Høye Journal: Acta Psychiatr Scand Date: 2019-03-29 Impact factor: 6.392
Authors: Charlotte Woodhead; Mark Ashworth; Matthew Broadbent; Felicity Callard; Matthew Hotopf; Peter Schofield; Murat Soncul; Robert J Stewart; Max J Henderson Journal: Br J Gen Pract Date: 2016-04-25 Impact factor: 5.386